All In Biotech

Drug Trial Radar · NCT05556343

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO)

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

18

Actual

Start

Jan 18, 2023

Primary completion

Aug 19, 2024

Study completion Feb 27, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Sep 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MYK-224 in participants with obstructive Hypertrophic Cardiomyopathy (oHCM)

Conditions

  • Cardiomyopathy, Hypertrophic

Interventions

  • MYK-224Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Adverse Events and Serious Adverse EventsTime frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
  2. Part A: Number of Participants With at Least One Event of ArrhythmiasTime frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
  3. Part A: Number of Participants With at Least One Event of Appropriate Implantable Cardioverter Defibrillator Therapy and Resuscitated Cardiac ArrestTime frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
  4. Part A: Change From Baseline in Vital Signs - Heart RateTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  5. Part A: Change From Baseline in Vital Signs - Mean Systolic Blood PressureTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  6. Part A: Change From Baseline in Vital Signs - Mean Diastolic Blood PressureTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  7. Part A: Change From Baseline in Vital Signs - Respiratory RateTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  8. Part A: Change From Baseline in Vital Signs - TemperatureTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  9. Part A: Change From Baseline in Vital Signs - WeightTime frame: Baseline and until treatment end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  10. Part A: Number of Participants With Abnormal Physical Examination ResultsTime frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  11. Part A: Number of Participants With Abnormal Electrocardiogram (ECG) ResultsTime frame: Baseline and until study end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  12. Part A: Number of Participants With Adverse Events Related to Clinical Laboratory Parameters (Hematology, Chemistry and Urinalysis)Time frame: Baseline and untill end date in Part A (Median 17.55 weeks and Maximum 54.9 weeks)
  13. Part A:Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) < 50%Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)
  14. Part A: Percentage of Participants With Incidence of Symptomatic Left Ventricular Ejection Fraction (LVEF) <= 30%Time frame: From first dose (Day 1) until study end date in Part A or 30 days after early termination date (Median 17.55 weeks and Maximum 54.9 weeks)

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • Local Institution - 0026

    La Jolla, California

  • Local Institution - 0014

    Los Angeles, California

  • Local Institution - 0016

    San Francisco, California

  • Local Institution - 0001

    Kansas City, Kansas

  • Local Institution - 0032

    New York, New York

  • Local Institution - 0013

    Durham, North Carolina

  • Local Institution - 0031

    Cincinnati, Ohio

  • Local Institution - 0015

    Cleveland, Ohio

  • Local Institution - 0024

    Portland, Oregon

  • Local Institution - 0021

    Nashville, Tennessee

  • Local Institution - 0025

    San Antonio, Texas

  • Local Institution - 0006

    Salt Lake City, Utah

  • Local Institution - 0029

    Milan, Italy

  • Local Institution - 0027

    Bologna, BO, Italy

  • Local Institution - 0005

    Florence, FI, Italy

  • Local Institution - 0030

    Wroclaw, Poland

  • Local Institution - 0011

    Katowice, Silesian Voivodeship, Poland

  • Local Institution - 0009

    A Coruña, Spain

  • Local Institution - 0023

    Barcelona, Spain

  • Local Institution - 0010

    Majadahonda, Spain

  • Local Institution - 0028

    Alicante, A, Spain

  • Local Institution - 0022

    Granada, GR, Spain

  • Local Institution - 0008

    Málaga, MA, Spain

  • Local Institution - 0002

    El Palmar, MU, Spain

  • Local Institution - 0003

    Valencia, V, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.